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Fatty acid synthesis 
A B S T R A C T   
The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D) is a potent regulator of immune function, 
promoting anti-inflammatory, tolerogenic T cell responses by modulating antigen presentation by dendritic cells 
(DC). Transcriptomic analyses indicate that DC responses to 1,25D involve changes in glycolysis, oxidative 
phosphorylation, electron transport and the TCA cycle. To determine the functional impact of 1,25D-mediated 
metabolic remodelling, human monocyte-derived DC were differentiated to immature (+vehicle, iDC), mature 
(+LPS, mDC), and immature tolerogenic DC (+1,25D, itolDC) and characterised for metabolic function. In 
contrast to mDC which showed no change in respiration, itolDC showed increased basal and ATP-linked respi-
ration relative to iDC. Tracer metabolite analyses using 13C -labeled glucose showed increased lactate and TCA 
cycle metabolites. Analysis of lipophilic metabolites of 13C-glucose revealed significant incorporation of label in 
palmitate and palmitoleate, indicating that 1,25D promotes metabolic fatty acid synthesis in itolDC. Inhibition of 
fatty acid synthesis in itolDC altered itolDC morphology and suppressed expression of CD14 and IL-10 by these 
cells. These data indicate that the ability of 1,25D to induce tolerogenic DC involves metabolic remodelling 
leading to synthesis of fatty acids.   
1. Introduction 
The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), is a 
potent immunomodulator, promoting innate antibacterial activity [1,2], 
whilst inhibiting inflammatory acquired immune responses [2,3]. 
Similar to its classical calciotropic actions, the immunomodulatory ac-
tivities of 1,25D are mediated by binding to the nuclear vitamin D re-
ceptor (VDR) [4], and concomitant regulation of transcription [5]. 
Whilst VDR expression is ubiquitous, the level of VDR is known to vary 
significantly in cells from the immune system. Resting T cells exhibit 
very low levels of VDR, with expression increasing dramatically 
following exposure to immunogens and T cell activation [6]. In this way 
1,25D is able to regulate activated T cells directly by supressing T helper 
1 (Th1) and Th17 function and promoting differentiation into regulatory 
T cells (Treg) [7]. However, 1,25D can also influence adaptive immunity 
T cell function via indirect effects on antigen presenting cells. Macro-
phages [8] and dendritic cells (DC) [9] express VDR, suggesting that 
regulation of antigen presentation to T cells may be a key function of 1, 
25D. 
The mechanisms by which 1,25D modulates DC function have still to 
be fully elucidated, and are likely to be dependent on specific DC 
phenotype, and the immune stimulus for the DC. However, these 
monocyte-derived immature DC (iDC) can be further modulated to 
generate DC with specific antigen-presenting cell characteristics. 
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Activation of iDC with immune modulators such as lipopolysaccharide 
(LPS) generates mature DC (mDC), with enhanced expression of cell 
surface antigens such as CD80 and CD86, co-stimulatory molecules 
required for antigen-presentation to T-cells [10]. Treatment of mDC 
with 1,25D suppresses expression of CD80/CD86 [9], and cytokines 
such as IL-12 associated with T cell activation [9]. However, 1,25D also 
increases DC expression of other cytokines such as IL-10 [11], to limit 
the maturation of DC [9,12], and promote a tolerogenic DC phenotype 
(tolDC) [13,14] which can elicit development of Treg [15]. 
To date studies of 1,25D responses in DC have focused on LPS- 
induced mDC, with the resulting cells being characterised as mature 
tolerogenic DC (mtolDC) [16,17]. Much less is known about DC effects 
of 1,25D in the absence of immune activation. Studies by our group and 
others have demonstrated expression of VDR in both iDC and mDC [9, 
18], indicating that both types of DC are potential targets for 1,25D. In 
murine bone marrow-derived DC, 1,25D was shown to regulate a greater 
number of genes in LPS-induced mtolDC relative to DC treated with 1, 
25D alone (referred to in the current study as immature tolerogenic DC 
(itolDC)) [19]. Whilst some 1,25D-regulated genes were common to 
both cell types, many were specific to mtolDC or itolDC [19]. Thus, the 
maturation context of DC responses to 1,25D is likely to be critical in 
defining the impact of vitamin D on innate immune DC function. 
Recent reports have shown that the effects of 1,25D on mDC are 
crucially dependent on metabolic remodelling. In monocyte-derived, 
LPS-induced mDC, pathway analyses showed that the dominant tran-
scriptomic effects of 1,25D involved changes in glucose metabolism, 
oxidative phosphorylation and the TCA cycle [20]. Specifically, 
short-term treatment of LPS-induced mDC with 1,25D induced an 
mtolDC phenotype that was dependent on glucose availability and 
glycolysis [20]. In studies using multiple gene expression repositories 
we have shown that the ability of 1,25D to promote metabolic remod-
elling via glycolysis, oxidative phosphorylation and the TCA cycle is 
common to many myeloid cell types including monocytes, iDC and mDC 
[21]. In the current study we have further defined the role of metabolic 
remodelling in mediating immunomodulatory effects of 1,25D by 
demonstrating increased fatty acid synthesis by DC in the absence of 
immunogenic stimulus. Inhibition of fatty acid synthase suppressed the 
ability of 1,25D to promote IL-10-secreting itolDC, indicating that 
regulation of lipid metabolism is central to the immunomodulatory ac-
tions of 1,25D. 
2. Materials & methods 
2.1. Isolation of primary human peripheral blood monocytes 
Healthy human peripheral blood mononuclear cells (PBMC) were 
obtained from fully anonymised blood cones obtained from the National 
Blood Service, Birmingham, UK, in accordance with ethical agreement 
ERN_14-0446. PBMC were isolated from whole blood leukocyte cones 
from healthy donors using LymphoPrep Separation Media (Stem Cell 
Technologies, Cambridge, UK) as per manufacturer’s instructions, and 
resuspended in ice-cold MACS (magnetic-activated cell sorting) buffer to 
achieve approximately 50million PBMCs per mL. CD14+ monocytes 
were isolated from PBMC using the EasySep Monocyte Isolation Kit 
(Stem Cell Technologies) as per manufacturer’s instructions. The yield of 
CD14+ monocytes achieved from 500 million PBMC was approximately 
50 million. The resulting monocytes were transferred to a new tube, and 
PBS added up to 15 mL. Following centrifugation at 1500 rpm for 5 min, 
pelleted CD14+ monocytes were re-suspended in Roswell Park Memo-
rial Institute (RPMI) 1640 Medium (Thermofisher, Loughborough, UK) 
supplemented with 5% L-glutamine (Sigma Aldrich, Gillingham, UK) 
and 10 % foetal bovine serum (FBS; Biosera, Heathfield, UK) to achieve 
2 million cells per mL. 
2.2. In vitro generation of monocyte-derived DC 
Individual donor monocyte preparations outlined above were used to 
generate the different DC phenotypes for each experiment. Each donor 
therefore acted as a replicate for each experiment, with associated intra- 
donor variability. For each donor, CD14+ monocytes were differenti-
ated into DC in vitro according to the schematic shown in Fig. 1A. 
Monocytes were cultured for 5 days with granulocyte macrophage- 
stimulating colony factor (GM-CSF; 800U/mL, Berlex Laboratories, 
Seattle, WA) and Interleukin-4 (IL-4; 400U/mL), in the presence or 
absence of 10 nM 1,25D (Enzo Life Sciences, Exeter, UK; diluted in RPMI 
1640 medium from 50 μg/mL stock), at 37 ◦C and 5% CO₂. Fresh me-
dium supplemented with GM-CSF and IL-4 was added on day 2 and day 5 
of culture, with the resulting day 6 cells being immature DC (iDC). The 
addition of 1 μg/mL LPS (from E. coli, Sigma Aldrich) for 24 h on day 6 
generated mature DC (mDC). Addition of 1,25D (10 nM) for all 6 days of 
culture in the absence of LPS was used to generate immature tolerogenic 
DC (itolDC) and the addition of LPS for the last 24 h of these cultures 
generated mature tolerogenic DC (mtolDC). In some cultures mito-
chondrial fatty acid synthase (FAS) was specifically inhibited using 25 
μM of 4-Methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid 
(C75, Sigma Aldrich) from day 0. 
2.3. Flow cytometry analysis of DC 
Approximately 50,000 cells were transferred directly from culture 
plates into flow cytometry tubes, washed once with PBS and centrifuged 
at 1500 rpm for 5 min. After removing the supernatant, each sample was 
re-suspended by gentle vortex in 100 μL LIVE/DEAD Fixable Near-IR 
Dead Cell Stain (1 μL stock in 1 mL PBS; Life Technologies) to stain 
for dead cells. Samples were incubated in the dark on ice for 20 min., 
and then washed with PBS and the supernatant discarded. Fluorescent 
cell surface staining antibodies were added to samples to a total of 100 
μL per sample in PBS. Following incubation on ice for 30 min., samples 
were washed again and the resulting pellet re-suspended in 200 μL PBS 
for immediate flow cytometry analysis, or fixed for subsequent analysis 
at a later date. All washing and staining stages were carried out in the 
absence of light. For all studies cells were acquired on a Dako Cyan flow 
cytometer (Dako Cytomation), median fluorescent intensity (MFI) was 
measured for each cell surface marker and data were analysed using 
FlowJo software (Tree Star version 8.8.6). Data were also shown as 
representative flow cytometry plots. All antibodies were purchased from 
eBioscience/Thermofisher or BD Biosciences and expression quantified 
relative to the appropriate isotype control. A full list of antibodies, cy-
tokines, volumes used and product numbers is shown in Supplemental 
Table 1. Rat IgG antibodies conjugated with matching fluorophores were 
used for the isotype control stain, and compensation colours were also 
added. 
2.4. Microscope fluorescence imaging 
For fluorescence microscopy imaging DCs were washed with PBS and 
stained with 100 nM MitoTracker Green FM (Invitrogen) diluted in 
RPMI 1640 medium without FBS at 37 ◦C for 25 min. Cells were washed 
and covered with mounting medium containing DAPI (VECTASHIELD) 
for nuclear staining. Images were taken using the Zeiss LSM780 confocal 
microscope. Two channels were selected: excitation at 490 nm – emis-
sion 416 for mitochondria stain based on MitoTracker Green FM and 
excitation at 360 nm and emission at 460 nm for nuclei stained with 
DAPI. 
2.5. Quantitative real-time PCR 
Total RNA was extracted by phenol/chloroform method after cell 
lysis in TRIzol (Life Technologies/Invitrogen). 0.3− 0.5 μg RNA was 
reverse transcribed with random hexamers using TaqMan reverse 
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transcription reagents (Thermofisher/Applied Biosystems). Quantitative 
real-time PCR for 18S rRNA, VDR, CYP24A1 and CYP27B1 was then 
performed on an Applied Biosystems 7900 machine using assays on 
demand from Applied Biosystems: 18S rRNA, (4319413E); VDR 
(Hs00118624 CE); CYP24A1 (Hs00167999_m1); CYP27B1 
(Hs01096154_m1). Amplification of cDNAs involved incubation at 50 ◦C 
for 2 min. and 95 ◦C for 10 min. followed by 40 cycles of 95 ◦C for 15 s 
and 60 ◦C for 1 min. mRNA expression was statistically analysed as raw 
delta Ct values and fold-change in expression as originally described for 
quantification of PCR products [22]. 
2.6. Measurement of oxygen consumption 
Measurement of mitochondrial oxygen consumption were performed 
based on previously reported studies [23,24]. Following the generation 
of different DC types using culture methods described above, the 
resulting DC populations were resuspended in serum-free RPMI at 37 ◦C 
and 3− 5 × 105 cell per assay and assessed for respiration using the 
following protocol. Samples were added to chambers in an Oroboros 
O2k-FluoRespirometer (Oroboros Inc., Innsbruck, Austria) and com-
pounds used to induce different types of respiration were then sequen-
tially added to these chambers via an integrated aperture in the 
FluoRespirometer, over a period of 12 min as follows: oligomycin at 2.5 
μM (inhibitor of ATP synthase – measure ATP-coupled respiration); 
FCCP at 1 μM, until maximal respiration; rotenone at 0.5 μM (inhibitor 
of complex I - measures complex II linked respiration); antimycin A at 
2.5 μM (inhibitor of complex III - stops respiration and measures residual 
oxygen consumption). Raw oxygen consumption rate changes were 
recorded over the 12 min period of analysis and processed to estimate 
different bioenergetic related parameters such as basal respiration, 
ATP-linked respiration and maximal capacity of ETC. 
2.7. Mass spectrometry analysis of 13C-glucose and 13C-glutamine 
metabolism 
To assess effects of 1,25D on glycolysis and the TCA cycle metabolic 
tracer analyses were carried out using uniformly-labeled 13C6-glucose or 
13C5-glutamine as substrates as described previously [25]. Briefly, in the 
last 24 h of cell culture, conventional medium was replaced by DMEM 
supplemented with 10 % FBS, [U-13C] glutamine (2 mM) or glucose (10 
mM). Following culture, cells were harvested and washed with NaCl (0.1 
%). Metabolite extraction was performed by a gradient of 2.5 parts 
methanol: 2.5 parts of chloroform: 0.625 parts of H2O containing 
D-6-acid glutaric as internal reference. The extracted polar fraction was 
Fig. 1. Regulation of DC phenotype by 1,25D. A. Schematic representation of the model for cell culture of human monocyte-derived DC. Immature DC (iDC), 
mature DC (mDC), immature tolerogenic DC (itolDC), mature tolerogenic DC (mtolDC). B. Representative flow cytometry analyses for CD11c, CD14, CD80, CD86 and 
HLA-DR in iDC, mDC, mtolDC and itolDC showing comparison between iDC vs itolDC, iDC vs mDC and mDC vs mtolDC. C. Median fluorescence intensity values for 
CD11c, CD14, CD40, CD80, CD83, CD86, CD209 and HLA-DR in iDC, mDC, mtolDC and itolDC. D. Expression of mRNA for VDR, CYP24A1 and CYP27B1 in iDC, 
mDC, mtolDC and itolDC. Data are shown as: raw delta Ct values with associated statistical analysis (upper panel); fold-change in mRNA expression (lower panel). 
Data show individual replicate cell preparation values and median and upper/lower quartiles for n = 5 replicate donor analyses. * = statistically different from iDC 
values, p < 0.05, ** p < 0.01, *** p < 0.001. 
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analysed to study metabolism in glycolysis and TCA cycle. For analysis 
of fatty acid synthesis, the extracted non-polar fraction was utilised. In 
the case of the latter, the replacement of RPMI media with DMEM media 
was carried out in day 3 of cell culture. In this case, a gradient of 50 % 
chloroform: 50 % methanol containing C17:0, heptadecylic acid (Sigma 
Aldrich) was used as an internal reference. The non-polar fraction was 
extracted and dried with nitrogen gas. Metabolites that differ in mass 
due to carbon composition are known as isotopologues and were rep-
resented as M + n; where n is the number of 13C atoms incorporated. 
Using mass spectrometry, metabolites and their isotopologues were 
quantified and their relative abundance was calculated. Metabolite 
abundance was normalized by the internal standard and total ion count. 
The incubation for labelled 13C-substrates was determined based on 
previous reports from our group in which a steady state equilibrium was 
achieved [25,26]. 
2.8. Statistical analysis 
GraphPad Prism 7.0a software (GraphPad) was used for graphical 
summary and statistical analysis. FACS and ELISA data was statistically 
tested using one-way ANOVA with post-hoc Tukey’s test. For each test a 
95 % confidence level was used. For Oxigraph data, raw data was pro-
cessed to obtain basal respiration, maximal capacity and ATP linked 
respiration parameters. For each comparison, an n = 4 separate donor 
monocyte preparations were used for each treatment. To find significant 
differences in these respiration parameters a paired student’s t test was 
applied for each parameter comparing the 1,25D treated (itolDC cells) to 
untreated (iDC). For mass spectrometry analysis of metabolism relative 
abundance of isotopologues of different metabolites was measured. 
These isotopologues differ in the number of “labelled” carbons repre-
sented as M + n, where n is the number of carbons. For each experiment 
(glucose, glutamine and palmitate labelled experiment) iDC and itolDC 
were obtained from 5 different donors. To report significance differences 
in the relative abundance of each isotopologue of a metabolite, multiple 
paired student’s t test were performed. Metabolite tracer pool and 
glucose aportation: To compare differences in the overall metabolite 
pool and glucose usage to form polar metabolites between iDC and 
itolDC a paired student’s t test was used. 
3. Results 
3.1. 1,25D regulates DC phenotype in the presence and absence of 
immunogenic stimulus 
Differentiation of human peripheral blood monocytes to DC using 
1,25D in the presence or absence of LPS was associated with specific 
changes in DC phenotype (Fig. 1). Relative to vehicle-treated iDC, LPS- 
induced mDC showed increased numbers of HLA-DR+ cells, and 
increased MFI for CD11c, CD80, CD83, CD86, CD209 and HLA-DR 
(Fig. 1B and C), consistent with a mature antigen-presenting pheno-
type [27,28]. Relative to mDC, mtolDC demonstrated decreased HLA-DR 
positivity, and suppressed CD80, CD83, CD86, CD209 and HLA-DR MFI 
(Fig. 1B and C), consistent with a tolerogenic DC phenotype [29,30]. The 
tolerogenic nature of 1,25D-induced itolDC is also illustrated by com-
parison with vehicle-treated iDC, with decreased numbers of CD80+ and 
HLA-DR+ cells, and CD14+ cells in itolDC. The MFI for CD80, CD86 and 
HLA-DR was also decreased in itolDC relative to iDC, whilst CD14 MFI 
was increased (Fig. 1B and C). Further characterisation of the DC 
sub-types was carried out by analysing expression of mRNAs for 
different components of the vitamin D signalling and metabolic system 
(Fig. 1D). VDR was expressed by all DC types, but was increased in 
LPS-treated DC (2.3- and 3.4-fold respectively in mDC and mtolDC). 
Both itolDC and mtolDC exhibited sensitivity to 1,25D as demonstrated 
by increased expression of the vitamin D catabolic enzyme CYP24A1 
(7.4- and 20.2-fold respectively in itolDC and mtolDC). By contrast, 
treatment with LPS alone (mDC) suppressed CYP24A1. LPS treatment 
also induced expression of the vitamin D activating enzyme CYP27B1 
(75.5- and 55.7-fold respectively in mDC and mtolDC), but treatment 
with 1,25D alone had no effect on CYP27B1. Subsequent data analyses 
were colour-coded according to phenotype colours shown in Fig. 1A. 
3.2. 1,25D-induced itolDC are characterised by increased oxidative 
phosphorylation 
Oxygen consumption rates (OCR) were measured in different pop-
ulations of DC to assess the effects of 1,25D and LPS on metabolic 
remodelling in the different DC phenotypes (Fig. 2). Relative to iDC, 
1,25D-induced itolDC showed increased basal respiration and ATP- 
linked respiration. By contrast, induction of mDC via LPS-treatment 
had no significant effect on basal, ATP-linked or maximal respiration 
(Fig. 2). The effects of 1,25D on OCR were associated with 6-day 
treatment, as iDC or treated with 1,25D for 24 h showed no significant 
changes in OCR (data not shown). 
3.3. 1,25D-induced itolDC show increased TCA cycle metabolism 
Data in Figs. 1 and 2 indicate that DCs treated with 1,25D alone show 
an enhanced tolerogenic phenotype (itolDC) which was associated with 
increased mitochondrial respiration. Further studies were therefore 
carried out to more precisely define the metabolic remodelling induced 
by 1,25D in itolDC. DCs treated with fully labelled U-13C6-glucose for the 
final 24 h of culture were analysed by mass spectrometry to quantify 
incorporation of the isotope into the resulting polar (hydrophilic) tracer 
metabolites (Fig. 3). The pathway for incorporation of 13C6-glucose into 
metabolites via glycolysis and the TCA cycle is shown in Fig. 3A. 
Following glycolysis, the carbons from 13C2-acetyl-CoA are committed 
to the TCA cycle through citrate synthase, and remain in every metab-
olite generated in the first round of the cycle, reflected in the relative 
abundance of m + 2 isotopomers (Fig. 3B). Further incorporation of 13C- 
acetyl-CoA in a second round of the TCA cycle generates m + 4 and m +
6 isotopomers of citrate which were also increased in itolDC. M + 3 and 
mM + 5 isotopomers reflecting consecutive rounds of TCA cycle and 
Fig. 2. 1,25D-induced oxidative phosphorylation in itolDC. Oxygen con-
sumption rate (OCR) in IDC, itolDC and mDC. DC were differentiated for 6 days 
as described in Fig. 1A and then incubated in an Oroboros O2k- 
FluoRespirometer with integrated injection of specific factors to represent 
conditions of: i) basal respiration; ii) oligomycin-induced inhibition of ATP 
production; iii) FCCP uncoupling of electron transport chain; iv) antimycin A/ 
rotenone inhibition of electron transport over a 12 min period. Quantification 
of replicate donor experiments for basal respiration, ATP-linked respiration and 
maximal respiration capacity data was carried out for multiple time points with 
each cell type. Data are the individual replicate values median and upper/lower 
quartiles for n = 6 replicate donor analyses. * = statistically different from iDC 
values, p < 0.05. 
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Fig. 3. Tracer metabolite analysis of glucose metabolism in iDC and itolDC. A. Schematic representation for incorporation of 13C-labeled glucose in polar TCA 
cycle metabolites through glycolysis and TCA cycle metabolism. B. Relative abundance of unlabelled (M + 0) and 13C-labeled (M + 1, M + 2, M + 3, M + 4, M + 5, M 
+ 6) TCA cycle metabolites in iDC and itolDC. C Total % of TCA cycle metabolites in iDC vs itolDC produced due to glucose consumption. D. Total pool of TCA cycle 
metabolites in iDC vs itolDC (arbitrary units A.U.). Abbreviations: glucose 6-phosphate (G6P); fructose 6-phosphate (F6P); fructose 1,6-bisphosphate (F16BP); 
glyceraldehyde 3-phosphate (GA3P); dihydroacetone phosphate (DHAP); 1,3-bisphosphoglyceric acid (13BPG); 3-phosphoglyceric acid (3 PG); 2-phosphoglyceric 
acid (3 PG); phosphoenolpyruvic acid (PEP); pyruvate (PYR); lactate (LAC); acetyl-CoA (Ac-CoA); citrate (CIT); aconitate (ACO); itaconate (ITA); α-ketoglutarate 
(α-KG); glutamate (GLU); succinate (SUC); fumarate (FUM); malate (MAL); oxalo-acetate (OAA); aspartate (ASP). Data for Total % of TCA cycle metabolites and Total 
pool of TCA cycle metabolites are shown as the individual replicate values and mean ± SD for n = 5 separate donor monocyte preparations. Data for relative 
abundance of TCA metabolites are shown as mean ± SD for n = 5 separate donor monocyte preparations. * = itolDC values statistically different from iDC, p < 0.05, 
** p < 0.01, *** p < 0.001. 
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pyruvate carboxylase activity were also enhanced in itolDC (Fig. 3B). 
Consistent with the 1,25D-induced glycolysis and TCA cycle shown 
in Fig. 3B, itolDC also showed higher incorporation of glucose carbons 
into citrate (66.91 %), aspartate (43.72 %), malate (47.37 %), fumarate 
(22.71 %) and lactate (47.09 %) relative to vehicle-treated iDC (27.69 
%, 9.79 %, 12.53 %, 5.9 % and 8.56 % respectively), whilst incorpora-
tion into succinate showed no significant change (Fig. 3C). Despite the 
changes in 13C-glucose incorporation outlined above, the total amount 
of each metabolite measured by mass spectrometry showed that only 
lactate showed significantly increased steady state levels in itolDC 
compared to untreated iDC (Fig. 3D). 
To determine the wider metabolic implications of increased uti-
lisation of glucose carbons by itolDC, further tracer metabolite analyses 
were carried out using 13C- glutamine as a substrate (Fig. 4A). In Fig. 3, 
there was incorporation of 13C-glucose into multiple isotopologues for 
each TCA metabolite (excluding succinate) in 1,25D-induced itolDC. By 
contrast, 13C-glutamine was only significantly incorporated into the m +
1 isotologue for malate and aspartate, and the m + 5 isotopologue for 
glutamate in itolDC (Fig. 4B). These data suggest that DC TCA responses 
to 1,25D predominantly involve metabolism of glucose. 
3.4. 1,25D induces fatty acid synthesis in itolDC 
Data in Figs. 3 and 4 show the effect of 1,25D on polar, hydrophilic 
metabolites derived from 13C6-glucose and 13C5-glutamine. To assess 
possible effects of 1,25D on hydrophobic metabolites, further analysis of 
the non-polar fraction of cell extracts after incubation with 13C-glucose 
was carried out (Fig. 5). The pathway from TCA cycle (citrate) to fatty 
acids is shown in Fig. 5A. The relative abundance of different fatty acid 
isotopomers (Fig. 5B) showed significant incorporation of 13C-glucose 
for only palmitate. However, analysis of the total pool of different fatty 
acids in iDC and itolDC (Fig. 5C) showed that both palmitate and pal-
mitoleate were increased significantly in 1,25D-induced itolDC. 
Collectively these data indicate that induction of itolDC by 1,25D is 
associated with a significant increase in de novo fatty acid synthesis via 
glucose and citrate. 
3.5. Inhibition of fatty acid synthesis suppresses itolDC induction by 
1,25D 
The functional significance of fatty acid synthesis in 1,25D-induced 
itolDC was assessed using the fatty acid synthase inhibitor C75 [31]. 
Immunofluorescence showed that, relative to the more rounded 
Fig. 4. Tracer metabolite analysis of glutamine metabolism in iDC and itolDC. A. Schematic representation showing incorporation of 13C-labeled glutamine in 
polar TCA cycle metabolites as a consequence of TCA cycle metabolism. B. Relative abundance of unlabelled (M + 0) and 13C-labeled (M + 1, M + 2, M + 3, M + 4, 
M + 5, M + 6) TCA cycle metabolites in iDC and itolDC. Abbreviations: acetyl-CoA (Ac-CoA); citrate (CIT); aconitate (ACO); α-ketoglutarate (α-KG); succinate (SUC); 
fumarate (FUM); malate (MAL); oxalo-acetate (OAA); aspartate (ASP). Data are shown as mean ± SD for n = 5 separate donor monocyte preparations. * = itolDC 
values statistically different from iDC, p < 0.05. 
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morphology of vehicle-treated iDC, treatment with 1,25D produced a 
pronounced dendritic morphology in itolDC. This effect was abrogated 
in itolDC treated with C75 which exhibited fewer dendrites and a more 
rounded morphology (Fig. 6A). Analysis of DC culture supernatants also 
showed that inhibition of fatty acid synthase by C75 suppressed IL-10 
production by itolDC (Fig. 6B). Flow cytometry showed that C75 had 
no effect on HLA-DR, CD80 or CD86 expression by iDC, itolDC or mDC, 
but was associated with significant suppression of 1,25D-induced CD14 
expression by itolDC (Fig. 6B). 
4. Discussion 
Regulation of cellular metabolism plays a critical role in immune 
function, promoting changes in energy production and biosynthesis that 
underpin key innate immune responses to infection and tissue damage, 
while providing the metabolic basis for expansion of lymphocyte func-
tion in adaptive immune responses [32]. Antigen presenting cells such 
as macrophages and DC are particularly dependent on the regulation of 
metabolic pathways to maintain phenotype plasticity, whilst integrating 
antibacterial responses and T cell activation with tolerogenic attenua-
tion of immune function to limit tissue damage [33,34]. Induction of 
glucose consumption and glycolysis plays a crucial role in the activation 
of DCs and their ability to acquire, process and present antigen [35]. 
Notably, inhibition of hexokinase, the first enzymatic step in glycolysis, 
potently blocks DC activation [35]. At least part of the glycolytic 
metabolic reprogramming associated with DC activation involves the 
production of lactate, with recent studies showing that lactate acts as a 
crucial signalling molecule for tolDC in the generation of regulatory T 
cells (Treg) [36]. However, DC tolerogenicity is also strongly influenced 
by lipid metabolism, with elevated glycolysis and electron transport 
being linked to increased fatty acid oxidation (FAO) in tolDC [37]. 
Previous studies by ourselves and others have shown that the tolero-
genic effect of 1,25D on DCs is fundamentally associated with metabolic 
reprogramming in the form of increased glycolysis, oxidative phos-
phorylation and TCA cycle activity [20,21]. In data presented here we 
show that treatment of DC with 1,25D alone is sufficient to generate 
itolDC that exhibit significant metabolic reprogramming independent of 
immune activation, with enhanced fatty acid synthesis playing a central 
role in the generation of the itolDC phenotype. 
The itolDC in the current study are phenotypically similar to previ-
ously reported tolDC generated using combined treatment with 1,25D 
(100 nM) and dexamethasone (DEX) [37], with decreased expression of 
CD86 and CD80, increased expression of CD14, and relatively little 
change in CD11c relative to mDC. 1,25D/DEX-tolDC showed similar 
glycolytic activity to LPS-induced mDC but glycolytic reserve, respira-
tory capacity and metabolic plasticity were significantly higher in tolDC 
[37]. Increased glycolysis and oxidative phosphorylation have also been 
described for tolDC induced by 1,25D in the absence of DEX. However, 
in this case 6 day treatment with 1,25D to generate tolDC was accom-
panied by activation with LPS for the final 24 h, thus generating an 
mtolDC phenotype [20]. Nevertheless, this study showed that the 
metabolic reprogramming induced by 1,25D in combination with LPS 
was distinct from that observed for other tolerogenic treatments such as 
DEX + LPS [20]. Specifically, 1,25D was shown to promote metabolic 
reprogramming via activation of PI3kinase-Akt-mTOR pathways, with 
inhibition of these pathways acting to inhibit the tolerogenic effects of 1, 
25D on DC. By contrast, the effects of other promoters of DC tolero-
genesis such as DEX and IL-10 were unaffected by manipulation of the 
PI3kinase-Akt-mTOR pathway [20]. These observations, in combination 
with the data present in the current study, indicate that 1,25D alone is 
Fig. 5. Tracer metabolite analysis of glucose metabolism to fatty acid precursors in iDC and itolDC. A. Schematic representation showing incorporation of 
13C-labeled glucose in non-polar (lipophilic) TCA cycle metabolites as a consequence of glycolysis and TCA cycle metabolism. B. Relative abundance of unlabelled 
carbon (M + 0) (0) and 13C-labeled isotopologue (M + 1 – M + 18) [1–18] in iDC and itolDC. C. Total pool of stearate, oleate, palmitoleate, and palmitate in iDC vs 
itolDC (arbitrary units, A.U.). Abbreviations: acetyl-CoA (Ac-CoA); citrate (CIT); aconitate (ACO); α-ketoglutarate (α-KG); succinate (SUC); fumarate (FUM); malate 
(MAL); oxalo-acetate (OAA). Data for the Total pool of stearate, oleate, palmitoleate, and palmitate are individual replicate values and mean ± SD for n = 5 separate 
donor monocyte preparations. Data for relative abundance of TCA metabolites are shown as mean ± SD for n = 5 separate donor monocyte preparations. * = itolDC 
values statistically different from iDC, p < 0.05, ** p < 0.01, *** p < 0.001. 
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sufficient to promote the metabolic reprogramming required for a tol-
erogenic DC phenotype. 
In addition to enhanced aerobic glycolysis and lactate production, 
1,25D + LPS-induced mtolDC have also been shown to exhibit increased 
TCA cycle activity. Tracer metabolite analysis using 13C-glucose has 
shown that 1,25D promotes 13C-labeling of several TCA metabolites, 
consistent with increased incorporation of glucose into the TCA cycle 
[38]. In the current study we observed a similar significant increase in 
TCA cycle flux in itolDC induced by 1,25D alone. Importantly, by using 
both 13C-glucose and 13C-glutamine as TCA cycle substrates, we were 
able to confirm that the metabolic reprogramming actions of 1,25D are 
focused primarily on strongly enhanced incorporation of glucose into 
lactate and the TCA cycle (Fig. 3B and C). Nevertheless, in general the 
overall concentrations of individual TCA metabolites were not signifi-
cantly altered in itolDC (Fig. 3D). This suggests that these metabolites 
are highly incorporated into other metabolic pathways in DC treated 
with 1,25D, and this was the primary rationale for carrying out further 
studies of lipophilic metabolites. 
Both glycolysis and the TCA cycle can contribute to further metabolic 
pathways such as the proteins and lipid synthesis. In the current study 
we have shown for the first time that metabolic reprogramming effects 
of 1,25D on glucose consumption, glycolysis and TCA cycle activity in 
DC are associated with increased generation of fatty acids. Fatty acid 
synthesis appears to play a pivotal role in the generation and survival of 
Fig. 6. Inhibition of fatty acid synthesis suppresses effects of 1,25D on CD14 and IL-10 in itolDC. A. Mitotracker and DAPI immunofluorescence in iDC and 
1,25D-induced itolDC treated with vehicle or the fatty acid synthase inhibitor C75 (10-25 μM). B Concentration of IL-10 in supernatants from iDC and 1,25D-induced 
itolDC cultured in the absence (vehicle, V) or presence of C75 (20 μM). C flow cytometric analysis of CD14, HLA-DR, CD80 and CD86 in iDC and 1,25D-induced 
itolDC cultured in the absence (vehicle, V) or presence of C75 (20 μM). Data are shown as frequency of expression for analysis of n = 4-5 separate donor PBMC 
preparations. * = statistically different from itolDC, p < 0.05, ** p < 0.01, *** p < 0.001. 
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DCs, with inhibition of FAS decreasing DC development but also 
enhancing T cell activation by DC, with these effects being mediated 
partly through increased ER stress [39]. In a similar fashion, exoge-
nously added polyunsaturated fatty acids have been shown to block T 
cell activation by DC [40]. It is therefore possible that the increased 
synthesis of fatty acids by 1,25D itolDC may act in a paracrine fashion to 
affect T cell responses. This need not necessarily be restricted to para-
crine actions on T cells, as previous studies have described potent effects 
of palmitic acid on DC function, with the fatty acid acting as a toll-like 
receptor 4 ligand [41]. Thus, synthesis of fatty acids may provide a 
mechanism for intra-DC signalling. 
It is important to recognise the effects of fatty acids on DC function 
may be dependent on the context of DC development, as hepatic DC with 
low levels of fatty acids showed a tolerogenic phenotype and promoted 
Treg generation [42]. Palmitate and palimoleate are fatty acid pre-
cursors but they may also themselves exert anti-inflammatory effects, 
with palmitoleate functioning as a lipokine to regulate AMP kinase [43], 
and suppress inflammation [44]. Collectively these observations indi-
cate that the generation of palmitate and palmitoleate from glucose may 
be a pivotal component of the metabolic function of 1,25D in DC. It was 
therefore interesting to note that although inhibition of FAS in itolDC 
resulted in profound changes in DC morphology, the cells remained 
viable and exhibited relatively modest changes in expression of cell 
surface antigens. Consistent with the itolDC IL-10 analyses presented 
here, previous studies of inflammatory macrophages have shown that 
inhibition of FAS significantly suppresses expression of several cytokine 
markers, including IL-10 [45]. Given the fundamental importance of 
IL-10 for DC tolerogenesis [46] and the fact that our results indicate that 
FAS may play a key role in the ability of 1,25D to promote IL-10 pro-
duction in tolerogenic DC, we suggest that fatty acid synthesis be a key 
metabolic pathway in the development of a tolerogenic phenotype in DC 
but further work is needed to understand the molecular links between 
the FAS pathway and DC phenotype. The role of CD14 in this process is 
less clear and the suppression of itolDC CD14 following FAS inhibition 
may simply reflect the elevated levels of CD14 in these cells. However, it 
is interesting to note that a subset of IL-10-secreting tolerogenic DC 
referred to as DC-10 have been described in vivo and in vitro, that express 
also express CD14 in contrast to iDC or mDC [47]. 
5. Conclusions 
Data presented in this study show that 1,25D alone is sufficient to 
metabolically reprogramme DC, with increased glycolysis and lactate 
generation, and enhanced TCA cycling leading to fatty acid synthesis. 
Inhibition of fatty acid synthesis was sufficient to alter the morpholog-
ical and IL-10 induction effects of 1,25D, indicating that this component 
of metabolism is crucial for DC tolerogenesis. However, it is likely that 
1,25D coordinates a spectrum of changes in DC metabolism, notably 
including the potent generation of lactate in itolDC. Recent studies have 
shown the lactate itself is a pivotal DC-metabolite that promotes the 
generation of Treg [36], so that the induction of itolDC by 1,25D may 
involve altered DC morphology and function via enhanced fatty acid 
synthesis, as well as indirect effects on T cells via lactate generation. 
Further studies are also required to assess the in vivo significance of these 
observations. Previous reports have shown that DC exhibit significant 
capacity for localised synthesis of 1,25D from precursor 25D [9], so that 
it is possible that the variations in circulating 25D that conventionally 
define human vitamin D ‘status’ may exert concomitant effects on the 
metabolic profile of DC. The impact of this on immune function in vivo 
will be an important facet of future studies of vitamin D 
supplementation. 
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